{"filing":{"accession_number":"0001104659-26-109819","cik":"0001612940","ticker":"PRQR","company_name":"ProQR Therapeutics N.V.","form":"6-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"tm2625923d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1612940/000110465926109819/tm2625923d1_6k.htm"},"events":[{"id":34479,"run_id":31726,"accession_number":"0001104659-26-109819","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The exhibit announces the appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to the Board of Directors as strategic AI advisor. These are discrete executive and board appointments that would materially affect investor assessment of the company's leadership and strategic direction, particularly given the appointees' prominent backgrounds (Hart from Eli Lilly's genetic medicines team; Wolf as co-founder and CSO of Hugging Face) and their direct relevance to ProQR's stated AI strategy for its Axiomer RNA editing platform.","company_name":"ProQR Therapeutics N.V.","ticker":"PRQR","filing_date":"2026-09-23","form":"6-K","submitted_at":null,"items":[{"id":38209,"accession_number":"0001104659-26-109819","item_number":"EX-99.1","item_title":"tm2625923d1_ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces the appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to the Board of Directors as strategic AI advisor. These are discrete executive and board appointments that would materially affect investor assessment of the company's leadership and strategic direction, particularly given the appointees' prominent backgrounds (Hart from Eli Lilly's genetic medicines team; Wolf as co-founder and CSO of Hugging Face) and their direct relevance to ProQR's stated AI strategy for its Axiomer RNA editing platform.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-23T12:02:41.169549+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38209,"accession_number":"0001104659-26-109819","item_number":"EX-99.1","item_title":"tm2625923d1_ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces the appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to the Board of Directors as strategic AI advisor. These are discrete executive and board appointments that would materially affect investor assessment of the company's leadership and strategic direction, particularly given the appointees' prominent backgrounds (Hart from Eli Lilly's genetic medicines team; Wolf as co-founder and CSO of Hugging Face) and their direct relevance to ProQR's stated AI strategy for its Axiomer RNA editing platform.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-23T12:02:41.169549+00:00","company_name":"ProQR Therapeutics N.V.","ticker":"PRQR","filing_date":"2026-09-23"}]}